Nikon

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

XenomatiX develops automotive Lidar solutions.

LumiThera, Inc. is a medical device company based in Poulsbo, Washington, that specializes in developing innovative treatment solutions aimed at improving visual function and preventing vision loss associated with debilitating eye diseases. Established in 2013, the company focuses on photobiomodulation (PBM) therapy, utilizing non-invasive light-emitting diodes (LED) and laser technologies to address both acute and chronic ocular conditions. LumiThera's flagship product, The Valeda, is designed specifically for the treatment of dry age-related macular degeneration (AMD) and other ocular disorders. By employing low-level light therapy, LumiThera aims to slow or halt the progression of blinding diseases, enhance visual acuity and contrast sensitivity, and reduce central drusen volume, ultimately providing healthcare providers with effective treatment options for their patients.

Optocomb is a development and sales of optical comb generators and their applications and related equipment company. Hikaricom connects production plants and assembly plants around the world, and works to stably connect factory shipping and receiving inspections.

LumiThera, Inc. is a medical device company based in Poulsbo, Washington, that specializes in developing innovative treatment solutions aimed at improving visual function and preventing vision loss associated with debilitating eye diseases. Established in 2013, the company focuses on photobiomodulation (PBM) therapy, utilizing non-invasive light-emitting diodes (LED) and laser technologies to address both acute and chronic ocular conditions. LumiThera's flagship product, The Valeda, is designed specifically for the treatment of dry age-related macular degeneration (AMD) and other ocular disorders. By employing low-level light therapy, LumiThera aims to slow or halt the progression of blinding diseases, enhance visual acuity and contrast sensitivity, and reduce central drusen volume, ultimately providing healthcare providers with effective treatment options for their patients.

wrnch is a computer vision and deep learning software company based in Montréal, Canada, specializing in human motion and activity recognition from video. Founded by Dr. Paul Kruszewski, a seasoned entrepreneur in AI, wrnch offers a real-time software platform that utilizes a deep learning engine for human pose estimation. This technology processes standard 2D video to generate 3D motion data in real-time, allowing for the tracking of distinct body parts across multiple camera feeds. The company's solutions cater to various industries, including robotics, retail, and entertainment, enabling developers to enhance their applications with advanced motion analysis capabilities. As a profitable startup, wrnch has garnered support from experienced investors and has been incubated by the deep tech accelerator TandemLaunch.

QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.

Velodyne LiDAR is a technology company based in Morgan Hill, California, specializing in the development and manufacturing of high-performance LiDAR sensors. Founded by David Hall in 2007, the company has established itself as a leader in providing 3D real-time perception systems for various commercial applications. Its innovative products serve a diverse range of industries, including autonomous vehicles, advanced driver assistance systems, robotics, unmanned aerial vehicles, smart cities, and security. Velodyne LiDAR's technology emphasizes safety, efficiency, and sustainability, enabling industries to enhance mobility and improve community living through advanced sensor solutions. The company is recognized for its broad portfolio of technologies and software, which offer flexibility and performance tailored to meet specific industry needs.

Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.

Unirobot Corporation, established in 2014 and headquartered in Tokyo, Japan, specializes in the development, manufacturing, and sale of next-generation social robots. The company focuses on creating innovative robots that enhance human interaction through advanced personal AI capabilities, including natural language processing. In addition to its core products, Unirobot is involved in the development of general embedded software related to its robotic systems. Through its research and development efforts, Unirobot aims to push the boundaries of social robotics, contributing to the evolution of human-robot communication and interaction.

Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.

Gatari Corporation develops a social virtual reality (VR) application in which the voice can be visualized for the purposes of communication. The company is headquartered in Japan.

Carbon, Inc. specializes in digital manufacturing solutions, focusing on the design, development, and production of advanced 3D printing technologies. The company's proprietary Digital Light Synthesis (DLS) technology incorporates digital light projection, oxygen-permeable optics, and programmable liquid resins to create high-quality parts with superior mechanical properties and surface finishes. Carbon's offerings include the SpeedCell system for streamlined production, additive manufacturing machines based on Continuous Liquid Interface Production (CLIP) technology, and automated Smart Part Washers. These innovations support various industries, including automotive, consumer products, dental, industrial, and life sciences, by enabling mass customization and on-demand inventory, while reducing waste and production time. Additionally, Carbon provides a range of polyurethane materials and consulting services to enhance manufacturing capabilities. Founded in 2013 by Dr. Joseph DeSimone and Philip DeSimone, Carbon is headquartered in Redwood City, California.

Founded in 2011, Tribogenics is developing low-cost, miniature x-ray solutions for applications in mining, industrial, military, medical imaging, and many other industries. Tribogenics employs technology developed at UCLA by leading scientists and is based in Los Angeles, California.

Optos plc is a retinal imaging company based in Dunfermline, United Kingdom, that specializes in the design, development, manufacturing, and marketing of ultra-widefield (UWF) imaging devices for eye-care professionals globally. Founded in 1992, the company produces high-resolution optomap images that facilitate the early detection and management of various retinal disorders, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Its product lineup includes advanced imaging devices such as the California af, California fa, California icg, Daytona, and Monaco, each tailored to different clinical needs and patient care levels. Additionally, Optos offers integrated software solutions, including OptosAdvance for clinical data management and OptosCloud for image storage. These innovations aim to enhance the capabilities of eye-care professionals while improving patient outcomes. Optos operates as a subsidiary of Nikon Corporation.

Healios is a biotechnology company focused on research, development, and manufacturing in the fields of cellular and regenerative medicine. The company is collaborating with RIKEN, a prominent research institute in Japan, to commercialize the first pharmaceutical transplantation of retinal pigment epithelium (RPE) cells derived from human induced pluripotent stem cells (hiPSCs) for the treatment of age-related macular degeneration (AMD). This innovative therapy aims to regenerate retinal function and enhance visual capabilities in individuals suffering from retinal degenerative diseases. Additionally, Healios is engaged in the development and sales of ophthalmological surgery adjuvants and is exploring organ anlage transplantation therapies. The capital raised by the company underscores its commitment to advancing therapeutics based on Nobel Prize-winning hiPSC technology and making significant contributions to the field of regenerative medicine.

Healios is a biotechnology company focused on research, development, and manufacturing in the fields of cellular and regenerative medicine. The company is collaborating with RIKEN, a prominent research institute in Japan, to commercialize the first pharmaceutical transplantation of retinal pigment epithelium (RPE) cells derived from human induced pluripotent stem cells (hiPSCs) for the treatment of age-related macular degeneration (AMD). This innovative therapy aims to regenerate retinal function and enhance visual capabilities in individuals suffering from retinal degenerative diseases. Additionally, Healios is engaged in the development and sales of ophthalmological surgery adjuvants and is exploring organ anlage transplantation therapies. The capital raised by the company underscores its commitment to advancing therapeutics based on Nobel Prize-winning hiPSC technology and making significant contributions to the field of regenerative medicine.